Table 3. Associations of discharge prescription for spironolactone with outcomes at 1 year post-discharge among Medicare beneficiaries hospitalized for heart failure with ejection fraction <45% and estimated glomerular filtration rate <45 mL/min/1.73m2.
| % (total events / total patients) Spironolactone on discharge | Hazard ratio† (95% CI); p-value | |||
|---|---|---|---|---|
|
| ||||
| No | Yes | Unadjusted | Propensity adjusted | |
| All-cause readmission | 70% (656/933) | 77% (160/207) | 1.24 (1.04–1.48); p=0.014 | 1.36 (1.13–1.63); p=0.001 |
| Heart failure readmission | 40% (370/933) | 44% (91/207) | 1.14 (0.91–1.44); p=0.260 | 1.02 (0.80–1.30); p=0.847 |
| All-cause mortality | 46% (432/933) | 49% (102/207) | 1.09 (0.88–1.35); p=0.441 | 1.05 (0.83–1.31); p=0.706 |
| All-cause mortality or readmission | 84% (779/933) | 91% (188/207) | 1.22 (1.04–.143); p=0.014 | 1.30 (1.09–1.54); p=0.003 |
†
Hazard ratios comparing patients receiving spironolactone on discharge with those not receiving it